Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Arcutis Biotherapeutics, Inc. (ARQT)

Arcutis appoints Dr. Robert Scott to board, expanding it from ten to eleven directors

Neutral Impact 2 of 5 leadership Written later

Arcutis Biotherapeutics increased its board from ten to eleven directors and appointed Dr. Robert Scott, a former chief medical officer at AbbVie, effective October 23, 2026. The filing describes him as independent and he joins the Nominating and Corporate Governance Committee, and the company said the appointment was announced in a press release on October 28, 2026.

Key points

  • Dr. Robert Scott, age 73, appointed as a Class II director with a term expiring at the 2028 annual meeting
  • Initial stock option award for 20,507 shares; annual equity award fair valued at approximately $350,000
  • Annual cash retainer of $50,000 for board service and $5,000 for Nominating and Corporate Governance Committee service, prorated

The filing

CompanyArcutis Biotherapeutics, Inc. (ARQT)
Form8-K, current report
Filed with the SECOct 28, 2026, 9:04 AM ET
Accession number0001628280-26-067752

Items reported: 5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 28, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.